IL15 and neoplasm: Anti-mPD1-IL15m exhibits more substantial anti-tumor effects than IL-15 super agonists/anti-mPD1/both combinations and is a promising molecule with a better safety profile than IL-15 super agonists (Xu et al., 2021).